Lauren E. Richards‐Peterson

Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of <scp>RIPK</scp>1 inhibitor <scp>GSK</scp>2982772 in healthy volunteers

Kathleen Weisel, Nicola Scott, Debra Tompson et al. · Pharmacology Research & Perspectives · 2017 · 130 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13

The Metabolic Drug-Drug Interaction Profile of Dabrafenib: In Vitro Investigations and Quantitative Extrapolation of the P450-Mediated DDI Risk

Sarah K. Lawrence, Dung N. Nguyen, Chet Bowen et al. · Drug Metabolism and Disposition · 2014 · 52 citations

Medicine, Pharmacokinetics, Pharmacology +17

Assessment of the drug interaction potential and single‐ and repeat‐dose pharmacokinetics of the BRAF inhibitor dabrafenib

A. Benjamin Suttle, Kenneth F. Grossmann, Danièle Ouellet et al. · The Journal of Clinical Pharmacology · 2014 · 46 citations

Medicine, Pharmacokinetics, Pharmacology +14

Metabolism and Disposition of Oral Dabrafenib in Cancer Patients: Proposed Participation of Aryl Nitrogen in Carbon-Carbon Bond Cleavage via Decarboxylation following Enzymatic Oxidation

David A. Bershas, Danièle Ouellet, Donna Mamaril-Fishman et al. · Drug Metabolism and Disposition · 2013 · 45 citations

Medicine, Oncology, Pharmacology +15

Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF V600 Mutation‐Positive Solid Tumors

Cathrine L. Denton, Elisabeth A. Minthorn, Stanley W. Carson et al. · The Journal of Clinical Pharmacology · 2013 · 38 citations

Pharmacy, Pharmacokinetics, Pharmacology +13